Original Articles : Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naive patients with chronic hepatitis Binfection

( Won Gil Chung ),( Hong Joo Kim ),( Young Gil Choe ),( Hyo Sun Seok ),( Chang Wook Chon ),( Yong Kyun Cho ),( Byung Ik Kim ),( Young Yool Koh ) 대한간학회 2012 Clinical and Molecular Hepatology(대한간학회지) Vol.18 No.2

Background/Aims: The aim of this study was to analyze the clinical impacts of obesity and hazardous alcohol use on the outcome of entecavir (ETV) therapy in chronic hepatitis B (CHB) patients. Methods: The medical records of 88 treatment-naive patients who were diagnosed with CHB and received ETV between March 2007 and September 2009 were analyzed retrospectively. Body mass index (BMI) values and Alcohol Use Disorders Identifi cation Test (AUDIT) scores were obtained at 6 months after the initiation of ETV (0.5 mg daily) treatment. Results: A BMI of 25 kg/m2 or more was recognized as an indicator of obesity, and a total AUDIT score of 8 or more was recognized as an indicator of hazardous alcohol use. Of the cohort, 24 patients (27.3%) were obese and 17 (19.3%) were hazardous alcohol users. The rate of seroconversion, alanine aminotransferase (ALT) normalization, and hepatitis B virus (HBV)-DNA negativity (<300 copies/mL) at 3, 6, and 12 months of treatment did not differ significantly between the normal-BMI and high-BMI groups. Moreover, the rate of seroconversion and HBV-DNA negativity at 3, 6, and 12 months of treatment did not diff er signifi cantly between the nonhazardous and hazardous alcohol users. However, the frequency of ALT normalization at 12 months was signifi cantly lower among hazardous alcohol users (91.5% vs. 70.6%; P=0.033). Conclusions: Obesity and hazardous alcohol drinking have no significant impact on the outcome of ETV treatment. However, the ALT normalization rate at 12 months after initiation of ETV treatment was signifi cantly lower among the hazardous alcohol users. (Clin Mol Hepatol 2012;18:195-202)

Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection

Won Gil Chung,Hong Joo Kim,Young Gil Choe,Hyo Sun Seok,Chang Wook Chon,Yong Kyun Cho,Byung Ik Kim,Young Yool Koh 대한간학회 2012 Clinical and Molecular Hepatology(대한간학회지) Vol.18 No.2

Background/Aims: The aim of this study was to analyze the clinical impacts of obesity and hazardous alcohol use on the outcome of entecavir (ETV) therapy in chronic hepatitis B (CHB) patients. Methods: The medical records of 88 treatment-naïve patients who were diagnosed with CHB and received ETV between March 2007 and September 2009 were analyzed retrospectively. Body mass index (BMI) values and Alcohol Use Disorders Identifi cation Test (AUDIT) scores were obtained at 6 months after the initiation of ETV (0.5 mg daily) treatment. Results: A BMI of 25 kg/m2 or more was recognized as an indicator of obesity, and a total AUDIT score of 8 or more was recognized as an indicator of hazardous alcohol use. Of the cohort, 24 patients (27.3%) were obese and 17 (19.3%) were hazardous alcohol users. The rate of seroconversion, alanine aminotransferase (ALT) normalization, and hepatitis B virus (HBV)-DNA negativity (<300 copies/mL) at 3, 6, and 12 months of treatment did not differ significantly between the normal-BMI and high-BMI groups. Moreover, the rate of seroconversion and HBV-DNA negativity at 3, 6, and 12 months of treatment did not diff er signifi cantly between the nonhazardous and hazardous alcohol users. However, the frequency of ALT normalization at 12 months was signifi cantly lower among hazardous alcohol users (91.5% vs. 70.6%; P =0.033). Conclusions: Obesity and hazardous alcohol drinking have no significant impact on the outcome of ETV treatment. However, the ALT normalization rate at 12 months after initiation of ETV treatment was signifi cantly lower among the hazardous alcohol users. (Clin Mol Hepatol 2012;18:195-202) Background/Aims: The aim of this study was to analyze the clinical impacts of obesity and hazardous alcohol use on the outcome of entecavir (ETV) therapy in chronic hepatitis B (CHB) patients. Methods: The medical records of 88 treatment-naïve patients who were diagnosed with CHB and received ETV between March 2007 and September 2009 were analyzed retrospectively. Body mass index (BMI) values and Alcohol Use Disorders Identifi cation Test (AUDIT) scores were obtained at 6 months after the initiation of ETV (0.5 mg daily) treatment. Results: A BMI of 25 kg/m2 or more was recognized as an indicator of obesity, and a total AUDIT score of 8 or more was recognized as an indicator of hazardous alcohol use. Of the cohort, 24 patients (27.3%) were obese and 17 (19.3%) were hazardous alcohol users. The rate of seroconversion, alanine aminotransferase (ALT) normalization, and hepatitis B virus (HBV)-DNA negativity (<300 copies/mL) at 3, 6, and 12 months of treatment did not differ significantly between the normal-BMI and high-BMI groups. Moreover, the rate of seroconversion and HBV-DNA negativity at 3, 6, and 12 months of treatment did not diff er signifi cantly between the nonhazardous and hazardous alcohol users. However, the frequency of ALT normalization at 12 months was signifi cantly lower among hazardous alcohol users (91.5% vs. 70.6%; P =0.033). Conclusions: Obesity and hazardous alcohol drinking have no significant impact on the outcome of ETV treatment. However, the ALT normalization rate at 12 months after initiation of ETV treatment was signifi cantly lower among the hazardous alcohol users. (Clin Mol Hepatol 2012;18:195-202)

Analysis of Fatty Acyl Groups of Diacyl Galactolipid Molecular Species by HPLC/ESI-MS with In-source Fragmentation

Gil, Ji-Hye,Hong, Jong-Ki,Choe, Joong-Chul,Kim, Young-Hwan Korean Chemical Society 2003 Bulletin of the Korean Chemical Society Vol.24 No.8

The structures of molecular species of galactolipids, such as monogalactosyl diacylglycerol (MGDG) and digalactosyl diacylglycerol (DGDG), isolated from wheat flour have been investigated using negative-ion electrospray ionization (ESI) mass spectrometry interfaced with high performance liquid chromatography (HPLC). According to the result of HPLC analysis, MGDG and DGDG were found to consist of mixtures of five and four molecular species, respectively. The galactolipids have been also analyzed to determine their fatty acid compositions, using HPLC/ESI-MS combined with in-source (or cone voltage) fragmentation. HPLC/ ESI-MS is very useful for one-step analysis of mixtures of galactolipids with a small sample quantity. Especially, the carboxylate anions produced in in-source fragmentations of the negative-ion of each component separated by HPLC provide valuable information on the composition of its fatty acyl chains.

Postmotem Metabolic Alterations of the Thalamus of Dog Brain with use of In Vivo H MRS

Choe, Bo-Young,Gil, Hack-Joon,Suh, Tae-Suck,Shinn, Kyung-Sub Catholic Medical Center 1995 Bulletin of the Clinical Research Institute Vol.23 No.1

기업의 소유지배구조가 무보증회사채의 신용등급 결정에 미치는 영향

전영순(Young Soon S. Cheon),최국현(Kuk Hyun Choe),길형용(Hyung Yong Gil) 한국경영학회 2006 經營學硏究 Vol.35 No.5

Differences in the serum immunoglobulin concentrations between dairy and beef calves from birth to 14 days of age

Chung-Gil Lee,Chai-Yong Lee,Byeong-suk Ahn,Young-Hun Jung,Chang-yong Choe,Dong-Soo Son,Tai-Young Hur,Guk-Hyun Suh 대한수의학회 2003 Journal of Veterinary Science Vol.4 No.3

쥐 프로트롬빈 cDNA 의 클로닝과 발현

김지영,노현모,최준호,최성일,곽혜련 한국유전학회 1993 Genes & Genomics Vol.15 No.1

A rat liver cDNA library was screened for a prothrombin cDNA using a cDNA fragment coding human prothrombin as a probe. Among about 50,000 plaques, 30 positive plaques were obtained by hybridization with ^(32)P-labelled probe. The cDNA insert from two of the positive λ DNA were selected for further analysis of the prothrombin cDNA. The DNA sequence of the cDNA coding a rat prothrombin has been determined. It consists of 1950 nucleotides and encodes an ORF of 1851 nucleotides, 22 bp noncoding regions at 5' end and 97 bp noncoding regions at 3' end. It does not have poly A tail and poly A addition signal, AATAAA. Our cloned prothrombin cDNA differs by 6 nucleotides from already cloned rat prothrombin cDNA. It shows 80% homology with human prothrombin. Comparative analysis of region having considerable sequence homology between human and rat prothrombin suggests that the functional and structural domains and post translational modification sites in rat prothrombin cDNA can be mapped. The signal peptide, the cleavage sites, γ-carboxylated region, glycosylation attachment sites and the cleavage sites by Factor Xa in rat prothrombin can be presumed by comparative analysis. The rat prothrombin cDNA was expressed in E. coli as a fusion protein using glutathione S-transferase vector system.

Effects of Boronic Acid on the Fluoride-selective Chemosignaling Behavior of a Merocyanine Dye

Cha, Sun-Young,Jeon, Hye-Lim,Choi, Myung-Gil,Choe, Jong-In,Chang, Suk-Kyu Korean Chemical Society 2010 Bulletin of the Korean Chemical Society Vol.31 No.5

The effects of boronic acid on the fluoride-selective chemosignaling behavior of a merocyanine dye were investigated. In the presence of phenylboronic acid (PBA), N-methylquinolinium-based merocyanine dye displayed fluoride-selective chromogenic signaling behavior over other commonly coexisting anions in the micromolar concentration range. Signaling is produced by a fluoride-induced displacement of the dye from its complex with PBA, resulting in a significant chromogenic signal for the fluoride ion. This signaling was successfully analyzed using a ratiometric analysis of the UV-vis absorption in response to changes in fluoride ion concentration. A PBA substituted with an electron withdrawing group was found to exhibit a more pronounced signal. Polymer-bound PBA also exhibited useful fluoride-selective signaling behavior.

High-Performance Photoconductivity and Electrical Transport of ZnO/ZnS Core/Shell Nanowires for Multifunctional Nanodevice Applications

Jeong, Sehee,Choe, Minhyeok,Kang, Jang-Won,Kim, Min Woo,Jung, Wan Gil,Leem, Young-Chul,Chun, Jaeyi,Kim, Bong-Joong,Park, Seong-Ju American Chemical Society 2014 ACS APPLIED MATERIALS & INTERFACES Vol.6 No.9

<P>We report the electrical and optical properties of ZnO/ZnS core/shell nanowire (NW) devices. The spatial separation of charge carriers due to their type II band structure together with passivation effect on ZnO/ZnS core/shell NWs not only enhanced their charge carrier transport characteristics by confining the electrons and reducing surface states in the ZnO channel but also increased the photocurrent under ultraviolet (UV) illumination by reducing the recombination probability of the photogenerated charge carriers. Here the efficacy of the type-II band structure and the passivation effect are demonstrated by showing the enhanced subthreshold swing (150 mV/decade) and mobility (17.2 cm<SUP>2</SUP>/(V s)) of the electrical properties, as well as the high responsivity (4.4 × 10<SUP>6</SUP> A/W) in the optical properties of the ZnO/ZnS core/shell NWs, compared with the subthreshold swing (464 mV/decade), mobility (8.9 cm<SUP>2</SUP>/(V s)) and responsivity (2.5 × 10<SUP>6</SUP> A/W) of ZnO NWs.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/aamick/2014/aamick.2014.6.issue-9/am500731n/production/images/medium/am-2014-00731n_0010.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/am500731n'>ACS Electronic Supporting Info</A></P>

Assessment of the efficacy of an attenuated live marker classical swine fever vaccine (Flc-LOM-BE^rns) in pregnant sows

Lim, Seong-in,Choe, SeEun,Kim, Ki-Sun,Jeoung, Hye-Young,Cha, Ra Mi,Park, Gil-Soon,Shin, Jihye,Park, Gyu-Nam,Cho, In-Soo,Song, Jae-Young,Hyun, Bang-Hun,Park, Bong-Kyun,An, Dong-Jun Elsevier Ltd. 2019 Vaccine Vol.37 No.27

<P><B>Abstract</B></P> <P>Here, we constructed an attenuated live marker classical swine fever (CSF) vaccine (Flc-LOM-BE<SUP>rns</SUP>) to eradicate CSF. This was done by taking infectious clone Flc-LOM, which is based on an attenuated live CSF vaccine virus (LOM strain), and removing the full-length classical swine fever virus (CSFV) E<SUP>rns</SUP> sequences and the 3′ end (52 base pairs) of the CSFV capsid. These regions were substituted with the full-length bovine viral diarrhoea virus (BVDV) E<SUP>rns</SUP> gene sequence and the 3′ end (52 base pairs) of the BVDV capsid gene. Sows were vaccinated with the Flc-LOM-BE<SUP>rns</SUP> vaccine 3 weeks before insemination and then challenged with virulent CSFV at the early, mid- or late stages of pregnancy. We then examined transplacental transmission to the foetuses. Piglets born to sows vaccinated with Flc-LOM-BE<SUP>rns</SUP> did not show vertical infection, regardless of challenge time. In addition, CSFV challenge did not affect the delivery date, weight or length of the foetus. Pregnant sows inoculated with the Flc-LOM-BE<SUP>rns</SUP> vaccine were anti-CSF E<SUP>rns</SUP> antibody-negative and anti-BVDV E<SUP>rns</SUP> antibody-positive. Challenge of pregnant sows with virulent CSFV resulted in anti-CSF E<SUP>rns</SUP> antibody positivity. These results strongly indicate that differential diagnosis can be conducted between the Flc-LOM-BE<SUP>rns</SUP> vaccinated animal and virulent CSFV affected animal by detecting antibody against BVDV E<SUP>rns</SUP> or CSF E<SUP>rns</SUP> gene. Therefore, the Flc-LOM-BE<SUP>rns</SUP> vaccine may fulfil the function of differential diagnosis which required for DIVA vaccine.</P> <P><B>Highlights</B></P> <P> <UL> <LI> The Flc-LOM-BE<SUP>rns</SUP> is live attenuated DIVA vaccine for CSFV. </LI> <LI> The Flc-LOM-BE<SUP>rns</SUP> vaccine protected foetuses from vertical transmission. </LI> <LI> The Flc-LOM-BE<SUP>rns</SUP> vaccine enables differential identification of serum antibodies. </LI> </UL> </P>